Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Next Previous
Trial Profile

A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Penpulimab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Renal cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 13 Sep 2022 Results (n=15) reporting safety and efficacy data from cohort 4 (patients with previously treated locally advanced or metastatic urothelial carcinoma) of this trial presented at the 47th European Society for Medical Oncology Congress
    • 16 Jun 2020 Planned number of patients changed from 140 to 150.
    • 16 Jun 2020 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top